keyword
MENU ▼
Read by QxMD icon Read
search

delayed CINV

keyword
https://www.readbyqxmd.com/read/29577093/evaluation-of-a-neurokinin-1-antagonist-in-preventing-multiple-day-cisplatin-induced-nausea-and-vomiting
#1
Quanfu Li, Wenjuan Wang, Gang Chen, Shuqin Deng, Caihong Jiang, Feng Chen, Jun Zhao, Hui Li, Xiaojun Bai, Yuliang Hu, Lenggaowa Da, Yungaowa Wu, Gaowa Jin
Objective: To perform a prospective non-randomized comparison of the effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment with the standard multiple-day cisplatin regimen for the prevention of cisplatin-induced nausea and vomiting (CINV). Methods: Patients being administered 3-day cisplatin-based chemotherapy (25 mg/m2 /d) who had never received aprepitant were given either the standard regimen (tropisetron and dexamethasone) or the aprepitant regimen (aprepitant plus tropisetron and dexamethasone)...
2018: Open Medicine (Warsaw, Poland)
https://www.readbyqxmd.com/read/29556812/getting-it-right-the-first-time-recent-progress-in-optimizing-antiemetic-usage
#2
Lee Schwartzberg
Recent years have witnessed significant improvements in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their prescribed chemotherapy regimens without compromising quality of life. This reduction in the incidence of CINV can be primarily attributed to the emergence of effective, well-tolerated antiemetic therapies, including serotonin (5-hydroxytryptamine or 5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and the atypical antipsychotic olanzapine...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29556808/cinv-still-troubling-patients-after-all-these-years
#3
Matti Aapro
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects experienced by patients with cancer. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways. The emergence of receptor antagonists targeting serotonin and neurokinin-1 have revolutionized the prevention of CINV, significantly reducing the impact of this side effect and improving patient quality of life...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29547608/cisplatin-based-therapy-and-cinv-optimal-antiemetics-during-germ-cell-testicular-cancer-treatment
#4
Meghan Mastrangelo
BACKGROUND: Cisplatin-based chemotherapy regimens are the backbone of chemotherapy for germ cell testicular cancer. Cisplatin is administered for five days, causing an overlap of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Although CINV is widely researched, studies involving multiday chemotherapy regimens are limited. OBJECTIVES: This article synthesizes the research in antiemetics used in multiday cisplatin-based chemotherapy regimens and provides recommendations to optimize antiemetic therapy...
April 1, 2018: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29546524/prediction-of-chemotherapy-induced-nausea-and-vomiting-from-patient-reported-and-genetic-risk-factors
#5
Sonam Puri, Kelly A Hyland, Kristine Crowe Weiss, Gillian C Bell, Jhanelle E Gray, Richard Kim, Hui-Yi Lin, Aasha I Hoogland, Brian D Gonzalez, Ashley M Nelson, Anita Y Kinney, Stacy M Fischer, Daneng Li, Paul B Jacobsen, Howard L McLeod, Heather S L Jim
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) is common among cancer patients. Early identification of patients at risk for CINV may help to personalize anti-emetic therapies. To date, few studies have examined the combined contributions of patient-reported and genetic risk factors to CINV. The goal of this study was to evaluate these risk factors. METHODS: Prior to their first chemotherapy infusion, participants completed demographic and risk factor questionnaires and provided a blood sample to measure genetic variants in ABCB1 (rs1045642) and HTR3B (rs45460698) as well as CYP2D6 activity score...
March 15, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29510613/a-randomized-double-blind-placebo-controlled-study-of-the-safety-and-efficacy-of-olanzapine-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-receiving-moderately-emetogenic-chemotherapy-results-of-the-korean-south-west-oncology
#6
So-Yeon Jeon, Hye Sook Han, Woo Kyun Bae, Moo-Rim Park, Hyeok Shim, Sang-Cheol Lee, Se-Il Go, Hwan Jung Yun, Yong-Jin Im, Eun-Kee Song
Purpose: Data on the efficacy of olanzapine in patients receiving moderately emetogenic chemotherapy (MEC) are limited. This study aimed to evaluate and compare the efficacy of olanzapine versus placebo in controlling nausea and vomiting in patients receiving MEC. Materials and Methods: We conducted a randomized, double-blind, placebo-controlled study to determine whether olanzapine can reduce the frequency of chemotherapy-induced nausea and vomiting (CINV) and improve the quality of life (QOL) in patients receiving palonosetron and dexamethasone as prophylaxis for MEC-induced nausea and vomiting...
February 27, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29417850/efficacy-of-ginger-in-ameliorating-acute-and-delayed-chemotherapy-induced-nausea-and-vomiting-among-patients-with-lung-cancer-receiving-cisplatin-based-regimens-a-randomized-controlled-trial
#7
Xiangfeng Li, Ying Qin, Wei Liu, Xiao-Yu Zhou, Ya-Nan Li, Li-Ying Wang
Nausea and vomiting are among the most common and distressing side effects of chemotherapy. Additional antiemetic drugs are urgently needed to effectively manage and ameliorate chemotherapy-induced nausea and vomiting (CINV). The efficacy of ginger as an antiemetic modality for ameliorating CINV has not been established in previous studies. The aim of this study was to examine the efficacy of ginger, as an adjuvant drug to standard antiemetic therapy, in ameliorating acute and delayed CINV in patients with lung cancer receiving cisplatin-based regimens...
February 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29362306/-evaluation-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-hematological-malignancies-using-mascc-antiemesis-tool-mat
#8
Kana Oiwa, Naoko Hosono, Kazuhiro Itoh, Miyuki Ookura, Yasufumi Matsuda, Katsunori Tai, Takanori Ueda, Takahiro Yamauchi
Chemotherapy-induced nausea and vomiting(CINV)were prospectively evaluated using MASCC Antiemesis Tool(MAT) in patients with hematological malignancies in our institution. A total of 33 patients receiving 46 chemotherapy courses were evaluated. Although vomiting was not observed in the acute phase, nausea was seen in 22.6% and 32.3% of the patients in the acute and delayed phases, respectively. Thirty percent(25 cases)of the patients receiving highly emetogenic chemotherapy presented nausea in both the phases, while 40%(18 cases)of the patients receiving moderately emetogenic chemotherapy presented nausea in the delayed phase...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29345696/antiemetic-efficacy-and-safety-of-granisetron-or-palonosetron-alone-and-in-combination-with-a-corticosteroid-for-abvd-therapy-induced-nausea-and-vomiting
#9
Mayako Uchida, Tsutomu Nakamura, Kojiro Hata, Hiroyuki Watanabe, Yasuo Mori, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Keiko Hosohata, Toshihiro Miyamoto, Koichi Akashi
Background: Antiemetic effects and safety of granisetron or palonosetron alone and in combination with a corticosteroid against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with Hodgkin lymphoma receiving adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy. Methods: A total of 39 patients were eligible for this study. Before ABVD therapy, granisetron or palonosetron was intravenously administered with or without a corticosteroid (dexamethasone or hydrocortisone) and aprepitant...
2018: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/29310827/meta-analysis-of-safety-and-efficacy-of-rolapitant-nk-1-receptor-antagonist-for-prevention-of-chemotherapy-induced-nausea-and-vomiting
#10
REVIEW
Hussien Ahmed, Ali Mohamed Hammad, Abdelrahman Ibrahim Abushouk, Mohamed Zidan, Mohamed Salem, Ahmed Negida, Mohamed M Abdel-Daim
Although chemotherapeutic agents represent a cornerstone of cancer treatment, chemotherapy-induced nausea and vomiting (CINV) affect the patients' quality of life and basic daily activities. Rolapitant is a novel selective neurokinin-1 receptor antagonist (NK-1 RA), which was clinically approved for prevention of CINV. The aim of the present study is to synthesize evidence about the safety and efficacy of rolapitant in combination with other antiemetic agents for prophylaxis against CINV. We performed a web-based literature search of six authentic databases to identify eligible studies...
December 6, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/29248965/effectiveness-of-olanzapine-in-patients-who-fail-therapy-with-aprepitant-while-receiving-highly-emetogenic-chemotherapy
#11
Nikita Mehra, Prasanth Ganesan, Trivadi S Ganesan, Surendran Veeriah, Abirami Boopathy, Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Swaminathan Rajaraman, Sevaluxmy Ganesharajah, Tenali Gnana Sagar
Chemotherapy-induced nausea-vomiting (CINV) compromises the quality of life of patients with cancer. We present data on the effectiveness of olanzapine after failure of aprepitant in patients receiving highly emetogenic chemotherapy (HEC). A single-center prospective study was conducted, where patients ≥ 18 years who failed aprepitant, palonosetron, dexamethasone (APD) received olanzapine, palonosetron and dexamethasone (OPD) in the subsequent cycle of HEC. Failure of APD was defined as occurrence of ≥ grade 2 acute and/or delayed nausea ± vomiting...
December 16, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29244998/applicability-of-the-national-comprehensive-cancer-network-multinational-association-of-supportive-care-in-cancer-guidelines-for-prevention-and-management-of-chemotherapy-induced-nausea-and-vomiting-in-southeast-asia-a-consensus-statement
#12
Alexandre Chan, Matin M Abdullah, Wan Zamaniah B Wan Ishak, Annielyn B Ong-Cornel, Antonio H Villalon, Ravindran Kanesvaran
A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings, triple therapy with a serotonin (5-hydroxytryptamine-3 [5-HT3 ]) antagonist (preferably palonosetron), dexamethasone, and aprepitant is recommended for acute CINV prevention. In resource-restricted settings, triple therapy is still recommended, although a 5-HT3 antagonist other than palonosetron may be used...
December 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/29200685/a-study-on-utilization-and-evaluation-of-antiemetics-in-chemotherapy-induced-nausea-and-vomiting
#13
Gayathri Baburaj, Ansha Mariya Abraham, Lija George, Vijith Shetty, Rovin M Thempalangad, K S Rajesh, K C Bharath Raj
Purpose: Chemotherapy-induced nausea and vomiting (CINV) are the major adverse effects of cancer chemotherapy. The objectives of this study are to evaluate the utilization of antiemetics in CINV and to assess the emetogenicity of chemotherapy and to investigate the incidence of acute and delayed CINV. Methods: A prospective observational study was carried out in patients undergoing chemotherapy. A suitable data collection form was designed to collect data regarding patient's demographics, cancer type, chemotherapy regimen, antiemetic prescribed, and incidence of CINV according to the standard methods utilizing morrow assessment of nausea and emesis form...
July 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29187483/palonosetron-prevents-highly-emetogenic-chemotherapy-induced-nausea-and-vomiting-in-oral-cancer-patients
#14
MULTICENTER STUDY
Shinya Sento, Naoya Kitamura, Tetsuya Yamamoto, Koichi Nakashiro, Hiroyuki Hamakawa, Soichiro Ibaragi, Akira Sasaki, Natsumi Takamaru, Yoji Miyamoto, Isamu Kodani, Kazuo Ryoke, Katsuaki Mishima, Yoshiya Ueyama
BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients. PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy. RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29177570/genetic-risk-factors-for-chemotherapy-induced-nausea-and-vomiting-in-patients-with-cancer-receiving-cisplatin-based-chemotherapy
#15
Mari Yokoi, Daiki Tsuji, Kenichi Suzuki, Yohei Kawasaki, Masahiko Nakao, Hideaki Ayuhara, Yuuki Kogure, Kazuhiko Shibata, Toshinobu Hayashi, Keita Hirai, Kazuyuki Inoue, Toshihiro Hama, Koji Takeda, Makoto Nishio, Kunihiko Itoh
PURPOSE: Younger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30-50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment response. METHODS: This study included a subset of patients previously enrolled in a randomised controlled trial; 156 patients were evaluated. This study aimed to evaluate the role of pharmacogenomic polymorphisms relevant to antiemetic response in patients with cancer receiving cisplatin-based chemotherapy...
November 24, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29115898/augmented-reversal-of-cisplatin-induced-delayed-gastric-emptying-by-amla-emblica-officinalis-fruit-extract-in-sprague-dawley-rats
#16
Asad Ahmad, Mohammad Khushtar, Ranjan Kumar, Badruddeen, Ambreena Riyaz, Mohammad Irfan Khan, Azizur Rahman
Despite the availability of effective antiemetics, control of acute and delayed chemotherapy-induced nausea and vomiting (CINV) is often suboptimal and there is need of an inexpensive and safer alternative. Thus, this study was designed to evaluate the effect of Emblica officinalis Gaertn (Euphorbiaceae) fruit extract (EEEO) on cisplatin-induced delayed gastric emptying in Sprague-Dawley rats so that Emblica officinalis can be clarified for its application in CINV as a potential candidate. Groups I, II, III, IV, and V rats were pretreated orally with 1% carboxymethyl cellulose (CMC, 1 mL/kg), 1% CMC (1 mL/kg), EEEO (250 mg/kg), EEEO (500 mg/kg), and ondansetron (3 mg/kg), respectively, for 5 consecutive days...
November 8, 2017: Journal of Dietary Supplements
https://www.readbyqxmd.com/read/29080920/preventing-chemotherapy-induced-nausea-and-vomiting-in-patients-with-lung-cancer-efficacy-of-nepa-netupitant-palonosetron-the-first-combination-antiemetic
#17
Paul J Hesketh, Marco Palmas, Pierre Nicolas
PURPOSE: Patients receiving platinum-based chemotherapy are at high risk of chemotherapy-induced nausea and vomiting (CINV), a distressing side effect of treatment. This post-hoc subgroup analysis of two pivotal trials evaluated the efficacy of NEPA in preventing CINV in subsets of patients with lung cancer who received cisplatin or carboplatin. METHODS: In each study, the efficacy endpoints complete response (CR; defined as no emetic episodes and no rescue medication) and no significant nausea (NSN; defined as a score of < 25 mm on a visual analog scale of 0-100 mm) during the acute (0-24 h), delayed (25-120 h), and overall (0-120 h) phases post-chemotherapy in cycle 1 (study 1) and cycles 1-4 (study 2) were assessed...
October 28, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29057666/granisetron-a-review-of-pharmacokinetics-and-clinical-experience-in-chemotherapy-induced-nausea-and-vomiting
#18
REVIEW
Anastasia Spartinou, Vasileia Nyktari, Alexandra Papaioannou
Chemotherapy induced nausea and vomiting (CINV) are major side effects of chemotherapy and a great burden to patients' quality of life. Serotonin and substance P are the major neurotransmitters involved in the pathophysiology of CINV, but in spite of new antiemetics no completely effective regime exists for its prevention or treatment. Areas covered: In this review the authors provide a detailed description of granisetron's chemistry pharmacokinetics, pharmacodynamics, toxicity and a brief review of clinical trials involving granisetron and the management of CINV...
December 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29055118/comparative-efficacy-and-tolerability-of-antiemetic-prophylaxis-for-adult-highly-emetogenic-chemotherapy-a-network-meta-analysis-of-143-randomized-controlled-trials
#19
Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao
Chemotherapy-induced nausea and vomiting (CINV) is one of the commonest side-effects among cancer patients. However, there is lacking of hierarchical evidences comparing different antiemetics against highly emetogenic chemotherapy. Therefore, we conducted a network meta-analysis to investigate their comparative efficacy and tolerability. Randomized controlled trials that compared different antiemetic categories for adult highly emetogenic chemotherapy were included after searching PubMed, Web of Science, Embase and Cochrane Central...
March 1, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28952201/a-phase-ii-randomised-study-to-evaluate-the-efficacy-of-aprepitant-plus-palonosetron-for-preventing-delayed-phase-cinv-associated-with-tc-therapy-in-gynaecological-cancer
#20
Yayoi Sugimori, Tsuyoshi Ota, Takafumi Ujihira, Tomonori Ishiguro, Daiki Ogishima
AIM: Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequently encountered side effects of cancer treatment. Severe CINV can lead patients to refuse chemotherapy, which ultimately affects cancer outcomes. The development of fairly new antiemetic agents, 5-hydroxytryptamine-3 receptor antagonists, palonosetron and neurokinin-1 receptor antagonists and aprepitant has reduced the risk and incidence of CINV. In this study, we assessed the efficacy of aprepitant plus palonosetron against palonosetron for CINV in patients receiving moderately emetic cancer chemotherapy (paclitaxel and carboplatin combination [TC] therapy)...
September 2017: Journal of Obstetrics and Gynaecology Research
keyword
keyword
119020
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"